Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial

CONCLUSION: For secondary prevention of cancer associated VTE, Apixaban 2.5 mg compared to 5 mg twice daily did not lower combined bleeding events. (EVE trial. NCT03080883).PMID:38537780 | DOI:10.1016/j.jtha.2024.03.011

Source: Thrombosis and Haemostasis - March 27, 2024 Category: Hematology Authors: Robert D McBane Charles L Loprinzi Tyler Zemla Alfonso Tafur Kristen Sanfilippo Jane Jijun Liu David A Garcia James Heun Krishna Gundabolu Adedayo A Onitilo Usha Perepu Monic R Drescher Stanislav Henkin Damon Houghton Aneel Ashrani Henny Billett Shaylene Source Type: research